• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Exp Clin Cancer Res . TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients

tetano

Editor, Senior Moderator
J Exp Clin Cancer Res


. 2020 Sep 23;39(1):200.
doi: 10.1186/s13046-020-01708-6.
TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients


Andrea Sacconi[SUP] 1 [/SUP], Sara Donzelli[SUP] 2 [/SUP], Claudio Pulito[SUP] 2 [/SUP], Stefano Ferrero[SUP] 3 4 [/SUP], Francesca Spinella[SUP] 5 [/SUP], Aldo Morrone[SUP] 6 [/SUP], Marta Rigoni[SUP] 3 7 [/SUP], Fulvia Pimpinelli[SUP] 8 [/SUP], Fabrizio Ensoli[SUP] 8 [/SUP], Giuseppe Sanguineti[SUP] 9 [/SUP], Raul Pellini[SUP] 10 [/SUP], Nishant Agrawal[SUP] 11 [/SUP], Evgeny Izumchenko[SUP] 12 [/SUP], Gennaro Ciliberto[SUP] 13 [/SUP], Aldo Giann?[SUP] 3 4 [/SUP], Paola Muti[SUP] 3 [/SUP], Sabrina Strano[SUP] 14 [/SUP], Giovanni Blandino[SUP] 15 [/SUP]



Affiliations

Abstract

Background: SARS-coronavirus-2 enters host cells through binding of the Spike protein to ACE2 receptor and subsequent S priming by the TMPRSS2 protease. We aim to assess differences in both ACE2 and TMPRSS2 expression in normal tissues from oral cavity, pharynx, larynx and lung tissues as well as neoplastic tissues from the same areas.
Methods: The study has been conducted using the TCGA and the Regina Elena Institute databases and validated by experimental model in HNSCC cells. We also included data from one COVID19 patient who went under surgery for HNSCC.
Results: TMPRSS2 expression in HNSCC was significantly reduced compared to the normal tissues. It was more evident in women than in men, in TP53 mutated versus wild TP53 tumors, in HPV negative patients compared to HPV positive counterparts. Functionally, we modeled the multivariate effect of TP53, HPV, and other inherent variables on TMPRSS2. All variables had a statistically significant independent effect on TMPRSS2. In particular, in tumor tissues, HPV negative, TP53 mutated status and elevated TP53-dependent Myc-target genes were associated with low TMPRSS2 expression. The further analysis of both TCGA and our institutional HNSCC datasets identified a signature anti-correlated to TMPRSS2. As proof-of-principle we also validated the anti-correlation between microRNAs and TMPRSS2 expression in a SARS-CoV-2 positive HNSCC patient tissues Finally, we did not find TMPRSS2 promoter methylation.
Conclusions: Collectively, these findings suggest that tumoral tissues, herein exemplified by HNSCC and lung cancers might be more resistant to SARS-CoV-2 infection due to reduced expression of TMPRSS2. These observations may help to better assess the frailty of SARS-CoV-2 positive cancer patients.

Keywords: HNSCC; MYC; SARS-CoV-2; TMPRSS2; microRNAs TP53.
 
Back
Top Bottom